Fasenra and Intestinal obstruction - a phase IV clinical study of FDA data

Summary:

Intestinal obstruction is reported as a side effect among people who take Fasenra (benralizumab), especially for people who are male, 20-29 old, have been taking the drug for 1 - 2 years also take Xolair, and have Asthma.

The phase IV clinical study analyzes which people have Intestinal obstruction when taking Fasenra. It is created by eHealthMe based on reports of 11,790 people who have side effects when taking Fasenra from the FDA, and is updated regularly.

What is Fasenra?

Fasenra has active ingredients of benralizumab. eHealthMe is studying from 11,805 Fasenra users. Check the latest studies of Fasenra.

What is Intestinal obstruction?

Intestinal obstruction is found to be associated with 1,884 drugs and 2,619 conditions by eHealthMe. Check the latest studies of Intestinal obstruction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

11,790 people reported to have side effects when taking Fasenra.
Among them, 11 people (0.09%) have Intestinal obstruction.

Could Fasenra cause Intestinal obstruction?

Among these 11 people:

How long have people been on Fasenra when they have Intestinal obstruction? *

What is the gender of people who have Intestinal obstruction when taking Fasenra? *

female: 18.18 %
male: 81.82 %

What is the age of people who have Intestinal obstruction when taking Fasenra? *

What are other drugs people take besides Fasenra? *

What are other side effects people have besides Intestinal obstruction? *

Weight Decreased: 5 people, 45.45%
Asthma: 5 people, 45.45%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 4 people, 36.36%
Bone Density Decreased: 4 people, 36.36%
Foot Fracture: 4 people, 36.36%
Heart Rate Increased: 4 people, 36.36%
Blood Pressure Systolic Increased: 4 people, 36.36%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 36.36%
Nasopharyngitis (inflammation of the nasopharynx): 4 people, 36.36%
Pain In Extremity: 4 people, 36.36%

What are the existing conditions these people have? *

Asthma: 10 people, 90.91%
Cystic Fibrosis (disease of the secretary glands): 4 people, 36.36%
Nausea (feeling of having an urge to vomit): 1 person, 9.09%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 9.09%
Drowsiness: 1 person, 9.09%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 9.09%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 9.09%
Back Pain: 1 person, 9.09%
Abdominal Discomfort: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Fasenra and have Intestinal obstruction?

- Check whether Intestinal obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fasenra:

Fasenra (11,805 reports)

Browse all side effects of Fasenra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intestinal obstruction:

Intestinal obstruction (1,884 drugs)

Browse all the conditions that are associated with Intestinal obstruction:

Intestinal obstruction (2,619 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on benralizumab (the active ingredients of Fasenra) and Fasenra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.